<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18077</article-id><article-id pub-id-type="doi">10.15690/vramn18077</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CARDIOLOGY AND CARDIOVASCULAR SURGERY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ КАРДИОЛОГИИ И СЕРДЕЧНО-СОСУДИСТОЙ ХИРУРГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hypertension and sex hormone levels in young and middle-aged men</article-title><trans-title-group xml:lang="ru"><trans-title>Связь артериальной гипертензии с андрогенным статусом у мужчин молодого и среднего возраста</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8160-5612</contrib-id><contrib-id contrib-id-type="spin">3153-8373</contrib-id><name-alternatives><name xml:lang="en"><surname>Orlova</surname><given-names>Iana A.</given-names></name><name xml:lang="ru"><surname>Орлова</surname><given-names>Яна Артуровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>YAOrlova@mc.msu.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-5730-4286</contrib-id><contrib-id contrib-id-type="spin">3601-1377</contrib-id><name-alternatives><name xml:lang="en"><surname>Sorokin</surname><given-names>Egor D.</given-names></name><name xml:lang="ru"><surname>Сорокин</surname><given-names>Егор Дмитриевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>srknegor@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7954-0437</contrib-id><contrib-id contrib-id-type="spin">9329-7628</contrib-id><name-alternatives><name xml:lang="en"><surname>Pavlova</surname><given-names>Zukhra Sh.</given-names></name><name xml:lang="ru"><surname>Павлова</surname><given-names>Зухра Шариповна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>zukhra73@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2015-4712</contrib-id><contrib-id contrib-id-type="spin">3541-2077</contrib-id><name-alternatives><name xml:lang="en"><surname>Plisyuk</surname><given-names>Alina G.</given-names></name><name xml:lang="ru"><surname>Плисюк</surname><given-names>Алина Геннадьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>apl.cardio@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9939-3443</contrib-id><contrib-id contrib-id-type="spin">9133-3802</contrib-id><name-alternatives><name xml:lang="en"><surname>Raevskii</surname><given-names>Kirill P.</given-names></name><name xml:lang="ru"><surname>Раевский</surname><given-names>Кирилл Павлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>raevskiikp@my.msu.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4251-7545</contrib-id><contrib-id contrib-id-type="spin">6609-5468</contrib-id><name-alternatives><name xml:lang="en"><surname>Kamalov</surname><given-names>Armais A.</given-names></name><name xml:lang="ru"><surname>Камалов</surname><given-names>Армаис Альбертович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик</p></bio><email>armais.kamalov@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет имени М.В. Ломоносова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-10-10" publication-format="electronic"><day>10</day><month>10</month><year>2025</year></pub-date><volume>80</volume><issue>3</issue><issue-title xml:lang="en">Annals of the Russian Academy of Medical Sciences</issue-title><issue-title xml:lang="ru">Вестник Российской академии медицинских наук</issue-title><fpage>190</fpage><lpage>197</lpage><history><date date-type="received" iso-8601-date="2025-04-15"><day>15</day><month>04</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-09"><day>09</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Издательство "Педиатръ"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-04-10"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/18077">https://vestnikramn.spr-journal.ru/jour/article/view/18077</self-uri><abstract xml:lang="en"><p><bold>Background. </bold>Hypertension is a major cardiovascular condition and exhibits significant sexual dimorphism. The prevalence of hypertension in the general population could be associated with the state of sex hormone system to a large degree. Currently the data obtained on the relationship between sex hormones and blood pressure levels are insufficient.</p> <p><bold>Aims </bold>— to study the relationship between hypertension and sex hormone levels in young and middle-aged men in a retrospective cohort study setting.</p> <p><bold>Methods. </bold>A retrospective observational clinical trial was conducted. 698 medical records of male patients aged 18 to 59 years were analyzed. 508 patients with an average age of 41.1 ± 9.4 years, obesity prevalence of 48.2%, and hypertension prevalence of 52% were selected. Blood pressure levels, anthropometric data, levels of sex hormones, lipid panel and insulin resistance indicators were analyzed.</p> <p><bold>Results. </bold>In our study group, obesity and its abdominal form were more common among patients with hypertension. A decrease in the testosterone level (&lt; 12.1 nmol/l) was significantly more common among patients with hypertension (64.91 versus 41.98%; p ≤ 0.001). Differences in the prevalence of hyperestrogenism (estradiol level above 41.2 pg/ml) did not reach statistically significant values (29.43 versus 22.22%; p = 0.064). When dividing the study sample by estradiol tertiles, the groups significantly differed from each other in the prevalence of hypertension (p = 0.028). According to the results of multivariate logistic analysis, sex hormones made a significant contribution to the model of the presence of hypertension. High levels of estradiol were associated with a higher probability of hypertension, while lower levels reduced the probability of hypertension. The relationship between testosterone and hypertension was inverse: the higher the level of this hormone, the lower the probability of hypertension in young and middle-aged men.</p> <p><bold>Conclusions. </bold>Our study shows the presence of an independent relationship between the level of testosterone and estradiol and the presence of hypertension in young and middle-aged men.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Артериальная гипертензия (АГ) является важнейшим сердечно-сосудистым заболеванием и обладает значительным половым диморфизмом. Распространенность АГ в популяции может быть в значительной степени связана с состоянием системы половых гормонов. На настоящей момент получено недостаточно данных о связи андрогенного статуса и уровня артериального давления (АД).</p> <p><bold>Цель исследования </bold>— изучить связь АГ с андрогенным статусом у мужчин молодого и среднего возраста в рамках ретроспективного когортного исследования.</p> <p><bold>Методы. </bold>Проведено популяционное ретроспективное клиническое исследование. Проанализировано 698 медицинских карт пациентов мужского пола в возрасте от 18 до 59 лет. Отобрано 508 пациентов со средним возрастом 41,1 ± 9,4 года, распространенностью ожирения — 48,2%, АГ — 52%. Были проанализированы уровень АД, антропометрические данные, уровни гормонов половой оси, липидограмма и показатели инсулинорезистентности.</p> <p><bold>Результаты. </bold>В нашей выборке среди пациентов с АГ были более распространены ожирение и его абдоминальная форма. Снижение уровня тестостерона ниже границы нормы (&lt; 12,1 нмоль/л) значимо чаще встречалось среди пациентов с АГ (64,91 против 41,98%; p ≤ 0,001). Различия в распространенности гиперэстрогении (повышения уровня эстрадиола выше 41,2 пг/мл) не достигли статистически значимых показателей (29,43 против 22,22%; p = 0,064). При делении выборки по терцилям эстрадиола группы значимо различались между собой по распространенности АГ (p = 0,028). По результатам многофакторного логистического анализа половые гормоны вносили значимый вклад в модель наличия АГ. Высокие уровни эстрадиола были связаны с большей вероятностью АГ, более низкие уменьшали вероятность наличия АГ. Связь тестостерона с АГ носила обратный характер: чем выше уровень этого гормона, тем меньше вероятность АГ у мужчин молодого и среднего возраста.</p> <p><bold>Заключение. </bold>Наше исследование демонстрирует наличие независимой связи уровня тестостерона и эстрадиола с наличием АГ у мужчин молодого и среднего возраста.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>male</kwd><kwd>testosterone</kwd><kwd>estradiol</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>мужчины</kwd><kwd>тестостерон</kwd><kwd>эстрадиол</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Правительство РФ</institution></institution-wrap><institution-wrap><institution xml:lang="en">Government of the Russian Federation</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet. 2020;395(10226):795-808. doi:10.1016/S0140-6736(19)32008-2</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024 // Российский кардиологический журнал. – 2024. – Vol. 29, N 9. – P.6117. [Kobalava ZD, Konradi AO, Nedogoda S V., et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. doi:10.15829/1560-4071-2024-6117]</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control. Circulation. 2016;134(6):441-450. doi:10.1161/CIRCULATIONAHA.115.018912/SUPPL_FILE/MILLS_441.PDF</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Connelly PJ, Casey H, Montezano AC, Touyz RM, Delles C. Sex steroids receptors, hypertension, and vascular ageing. J Hum Hypertens. 2021;36(2):120. doi:10.1038/S41371-021-00576-7</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Бойцов С. А., Баланова Ю. А., Шальнова С. А., и др. АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ СРЕДИ ЛИЦ 25-64 ЛЕТ: РАСПРОСТРАНЕННОСТЬ, ОСВЕДОМЛЕННОСТЬ, ЛЕЧЕНИЕ И КОНТРОЛЬ. ПО МАТЕРИАЛАМ ИССЛЕДОВАНИЯ ЭССЕ // Кардиоваскулярная терапия и профилактика. – 2014. – Vol. 13, N 4. – P.4–14. [Boytsov S.A., Balanova Yu.A., Shalnova S.A., et al. ARTERIAL HYPERTENSION AMONG INDIVIDUALS OF 25–64 YEARS OLD: PREVALENCE, AWARENESS, TREATMENT AND CONTROL. BY THE DATA FROM ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14]</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ji H, Kim A, Ebinger JE, et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiol. 2020;5(3):255-262. doi:10.1001/JAMACARDIO.2019.5306</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Feldman HA, Longcope C, Derby CA, et al. Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87(2):589-598. doi:10.1210/JCEM.87.2.8201</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Marriott RJ, Harse J, Murray K, Yeap BB. Systematic review and meta-analyses on associations of endogenous testosterone concentration with health outcomes in community-dwelling men. BMJ Open. 2021;11(11). doi:10.1136/BMJOPEN-2020-048013</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: With illustrative examples from male and female populations. Steroids. 2009;74(6):512-519. doi:10.1016/J.STEROIDS.2009.01.008</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Swislocki ALM, Eisenberg ML. A Review on Testosterone: Estradiol Ratio—Does It Matter, How Do You Measure It, and Can You Optimize It? World J Mens Health. 2024;42. doi:10.5534/WJMH.240029</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Орлова Я.А., Сорокин Е.Д., Павлова З.Ш., и др. Оценка связи риска развития сердечно-сосудистых заболеваний с уровнем эстрадиола у мужчин молодого и среднего возраста // Кардиология. – 2023. – Vol. 63, N 9. – P.14–19. [Orlova IA, Sorokin ED, Pavlova ZS, Plisyuk AG, Kamalov AA. Linking Cardiovascular Risk With Estradiol Level in Men. Kardiologiia. 2023;63(9):14-19. doi:10.18087/CARDIO.2023.9.N2450]</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Бойцов С. А., Погосова Н. В., Аншелес А. А., и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации // Российский кардиологический журнал. – 2023. – Vol. 28, N 5. – P.5452. [Boytsov S.A., Pogosova N.V., Ansheles A.A., et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452]</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Эндокринология. Национальное Руководство. / под редакцией Дедова И. И., Мельниченко Г. А. – 2 издание – М.: ГЭОТАР-Медиа; 2024. [Dedov I.I., Mel'nichenko G. A., et al. Endokrinologiya. Nacionalnoe Rukovodstvo. 2nd ed. GEOTAR, media publishing group; 2024]</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Home - Mayo Clinic Laboratories. Accessed January 1, 2025. https://www.mayocliniclabs.com/</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2011;96(10):3007. doi:10.1210/JC.2011-1137</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Yeap BB, Marriott RJ, Antonio L, et al. Serum Testosterone is Inversely and Sex Hormone-binding Globulin is Directly Associated with All-cause Mortality in Men. J Clin Endocrinol Metab. 2021;106(2):E625-E637. doi:10.1210/CLINEM/DGAA743</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol. 2010;171(5):583-592. doi:10.1093/AJE/KWP415</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16(3):249-268. doi:10.1007/S11154-015-9323-2</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Qu M, Feng C, Wang X, et al. Association of Serum Testosterone and Luteinizing Hormone With Blood Pressure and Risk of Cardiovascular Disease in Middle-Aged and Elderly Men. J Am Heart Assoc. 2021;10(7). doi:10.1161/JAHA.120.019559</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chen BT, Tsai PJ, Jiann BP. Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction. Sex Med. 2025;12(6). doi:10.1093/SEXMED/QFAE089</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Visniauskas B, Kilanowski-Doroh I, Ogola BO, et al. Estrogen-mediated mechanisms in hypertension and other cardiovascular diseases. J Hum Hypertens. 2022;37(8):609. doi:10.1038/S41371-022-00771-0</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Орлова Я.А., Сорокин Е.Д., Павлова З.Ш., и др. Связь уровня эстрадиола с сердечно-сосудистыми осложнениями у мужчин по данным систематического обзора // Вестник Российской академии медицинских наук. – 2024. – Vol. 79, N 3. – P.205–215. [Orlova IA, Sorokin ED, Pavlova ZS, Plisyuk AG, Kamalov AA. Estradiol Level as a Risk Factor for Cardiovascular Endpoints in Men: A Systematic Review. Vestn Ross Akad Med Nauk. 2024;79(3):205-215. doi:10.15690/vramn17954]</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988;6(4):328???332. doi:10.1097/00004872-198804000-00010</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Swica Y, Warren MP, Manson JE, et al. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women’s Health Initiative hormone therapy trials. Menopause. 2018;25(7):753-761. doi:10.1097/GME.0000000000001067</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>The Coronary Drug Project: Findings Leading to Discontinuation of the 2.5-mg/day Estrogen Group. JAMA. 1973;226(6):652-657. doi:10.1001/JAMA.1973.03230060030009</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Jaiswal V, Sawhney A, Nebuwa C, et al. Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Prog Cardiovasc Dis. 2024;85:45-53. doi:10.1016/J.PCAD.2024.04.001</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Boardman HMP, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews. 2015;2015(3). doi:10.1002/14651858.CD002229.PUB4/MEDIA/CDSR/CD002229/URN:X-WILEY:14651858:MEDIA:CD002229:CD002229-CMP-003-05</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ding EL, Song Y, Manson JE, et al. Sex Hormone–Binding Globulin and Risk of Type 2 Diabetes in Women and Men. New England Journal of Medicine. 2009;361(12):1152-1163. doi:10.1056/NEJMOA0804381/SUPPL_FILE/NEJM_DING_1152SA1.PDF</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Li C, Ford ES, Li B, Giles WH, Liu S. Association of Testosterone and Sex Hormone–Binding Globulin With Metabolic Syndrome and Insulin Resistance in Men. Diabetes Care. 2010;33(7):1618-1624. doi:10.2337/DC09-1788</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Li J, Zheng L, Chan KHK, et al. Sex Hormone-Binding Globulin and Risk of Coronary Heart Disease in Men and Women. Clin Chem. 2023;69(4):374-385. doi:10.1093/CLINCHEM/HVAC209</mixed-citation></ref></ref-list></back></article>
